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Abstract: Background: The optimal duration of anticoagulation therapy (AT) following catheter-based
therapy of acute iliofemoral deep vein thrombosis (IFDVT) with stent placement is unknown. Theoreti-
cally, resolving the underlying obstructive iliac vein lesion by a stent may eliminate the main trigger for
recurrence, the post-thrombotic syndrome (PTS), and the need for extended-duration AT. Patients and
methods: From 113 patients with acute IFDVT who underwent endovascular thrombus removal and stent
placement, we compared patency rates and clinical outcomes between 58 patients on limited-duration AT
(3–12 month) and 55 patients on extended-duration AT (> 12 months). Results: Mean follow-up du-
ration was 26 ± 18 (range 3–77) months; it was 24 ± 18 (range 3–69) months after cessation of AT
in the limited-duration AT group. In comparison to patients with extended-duration AT, patients with
limited-duration AT were younger (38 versus 54 years; p < 0.001), more often female (74 % versus 49
%; p = 0.01), and had less often prior venous thromboembolism (VTE) (9 % versus 35 %; p = 0.001).
May-Thurner syndrome was more frequent in the limited-duration AT group (66 % versus 38 %; p =
0.004). Overall, primary and secondary patency rates at 24 months were 80 % (95 % CI, 70–87 %) and 95
% (95 % CI, 88–98 %), respectively, with no difference between the groups. Overall, 17 (15 %) patients
developed recurrent VTE, of which 14 (82 %) events were thrombotic stent occlusions, and 13 (76 %)
events occurred during AT. In the limited-duration AT group, 98 % patients were free from the PTS at
two years with a VTE recurrence rate of 3.5 per 100 patient years after cessation of AT. Conclusions:
In selected patients with acute IFDVT and patent venous stent, particularly in younger and otherwise
healthy patients with May-Thurner syndrome, it appears to be safe to discontinue AT 3–12 months after
endovascular treatment. Clinical Trial Registration: The study is registered on the National Institutes
of Health website (ClinicalTrials.gov; identifier NCT02433054).
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The optimal duration of anticoagulation therapy (AT) following catheter-based therapy 
of acute iliofemoral deep vein thrombosis (IFDVT) with stent placement is unknown. 
Theoretically, resolving the underlying obstructive iliac vein lesion by a stent may 
eliminate the main trigger for recurrence, the post-thrombotic syndrome (PTS), and the 
need for extended-duration AT.  
Patients and methods: 
From 113 patients with acute IFDVT who underwent endovascular thrombus removal 
and stent placement, we compared patency rates and clinical outcomes between 58 
patients on limited-duration AT (3-12 month) and 55 patients on extended-duration 
AT (>12 months). 
Results:  
Mean follow-up duration was 26±18 (range 3–77) months; it was 24±18 (range 3–69) 
months after cessation of AT in the limited-duration AT group. In comparison to 
patients with extended-duration AT, patients with limited-duration AT were younger (38 
versus 54 years; p<0.001), more often female (74% versus 49%; p=0.01), and had 
less often prior venous thromboembolism (VTE) (9% versus 35%; p=0.001). May-
Thurner syndrome (MTS) was more frequent in the limited-duration AT group (66% 
versus 38%; p=0.004). Overall, primary and secondary patency rates at 24 months 
were 80% (95%CI, 70-87%) and 95% (95%CI, 88-98%), respectively, with no 
difference between the groups. Overall, 17 (15%) patients developed recurrent VTE, 
of which 14 (82%) events were thrombotic stent occlusions, and 13 (76%) events 
occurred during AT. In the limited-duration AT group, 98% patients were free from the 
PTS at 2 years with a VTE recurrence rate of 3.5 per 100 patient years after cessation 
of AT.  
Conclusion: 
In selected patients with acute IFDVT and patent venous stent, particularly in younger 
and otherwise healthy patients with MTS, it appears to be safe to discontinue AT 3-12 
months after endovascular treatment.  
 
Clinical Trial Registration: 
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Venous thromboembolism (VTE) refers to deep vein thrombosis (DVT) and pulmonary 
embolism (PE) and is a major cause of morbidity and mortality.(1) Patients with 
iliofemoral DVT (IFDVT) are at greatest risk of VTE recurrence and the post-thrombotic 
syndrome (PTS). Compared to patients with DVT located in the popliteal or femoral 
veins, the rate of recurrent VTE during the initial 3 months of anticoagulation therapy 
(AT) was twice as high in patients with IFDVT (11.8 versus 5.3%).(2) Furthermore, with 
conservative therapy up to 30-50% of patients with IFDVT suffer from PTS within 2-8 
years after the index event.(3, 4) 
Early endovascular thrombus removal therapy, including catheter-directed 
thrombolysis (CDT) and pharmacomechanical thrombectomy (PMT), reduces the risk 
of moderate or severe PTS by removing the occluding thrombus and preventing 
secondary valve damage.(5-7) Up to 80% of patients with IFDVT have an underlying 
obstructive iliac vein lesion, which is thought to be the main trigger of thrombosis.(8, 
9) The elimination of the obstructing vein lesion by provisional stent placement after 
early thrombus removal aims at reducing the risk of the PTS and recurrent ipsilateral 
DVT.(10) 
AT is highly effective in preventing thrombus extension and VTE recurrence.(11) 
According to current consensus statement guidelines, extended duration of AT should 
be considered in patients with persistent risk factors for recurrence.(12-14) Due to the 
lack of scientific data, no recommendations regarding post-interventional AT are 
available in the current guidelines(13-15) and its management is highly 
inconsistent.(16) 
We postulate that in patients with descending IFDVT, early endovascular therapy with 
subsequent stent placement may reduce the need for extended-duration AT. In the 
present study, we analyzed patency, VTE recurrence rates, and clinical outcomes of 
patients with IFDVT following endovascular thrombus removal and stent placement 
treated with AT for a limited or extended duration.  
Methods 
Study design 
The present analysis was derived from the Swiss Venous Stent registry, an ongoing 
prospective study consecutively enrolling patients who received venous nitinol stents 
at the University Clinic of Angiology in Bern since July 2011. From this registry, we 
included all patients with acute IFDVT who underwent endovascular thrombus removal 
(CDT and/or PMT) followed by stent placement. Patients <18 years, or with a life 
expectancy <3 months were excluded. All patients had a minimum follow-up of three 
months, and at least one duplex ultrasound study. The registry and participant consent 
form were approved by the Swiss Ethics Committee on research involving humans. 
The study is registered on the National Institutes of Health website (ClinicalTrials.gov; 




Data and subgroup definitions 
For all enrolled patients, baseline demographic information, disease-specific 
information (thrombosis localization, involved venous segments, symptom onset, 
recurrence), comorbid conditions, risk factors, and anticoagulation therapy 
(anticoagulant type, treatment duration, bleeding complications) were recorded using 
a standardized case report form. Procedural data included type of catheter intervention 
(CDT/PMT), duration, dose and success of thrombolysis, and type and number of 
implanted stents.  
For the purpose of the present analysis, we predefined two patient subgroups: 
1. Limited-duration AT group: Patients with anticoagulation therapy discontinued 
after 3-12 months of treatment. 
2. Extended-duration AT group: Patients with ongoing anticoagulation therapy 
beyond 12 months. 
 
Diagnosis and initial anticoagulation therapy 
IFDVT was objectively confirmed by duplex ultrasound or contrast-enhanced 
computed tomography. Acute DVT was defined as symptom duration ≤14 days; 
subacute DVT as symptom duration of 15 to 28 days. On admission, an intravenous 
bolus of heparin of 80 units per kg body weight was administered. This was omitted, if 
the patient was already on anticoagulation therapy. Patients with CDT were treated 
with intravenous heparin administered through the venous access sheath throughout 
the thrombolysis procedure. Factor Xa levels were monitored frequently to target a 
factor Xa inhibition activity of 0.3 to 0.7 IU/ml. Within 24 h after full completion of the 
endovascular therapy, heparin was converted to either VKA (with overlapping LMWH 
for at least 5 days), rivaroxaban, or to parenteral anticoagulants in patients with active 
malignancies. The choice of anticoagulation therapy was up to the treating vascular 
specialist. We did not prescribe antiplatelet therapy after venous stent placement by 




Details on the CDT and PMT procedures have been published previously.(10, 17) 
Patients with extensive descending IFDVT involving the popliteal veins or the inferior 
vena cava usually received CDT with a standardized protocol of continuous infusion of 
20 mg recombinant tissue plasminogen activator (rt-PA) over 15 hours administered 
through a conventional lysis catheter (e.g. Craigg-McNamara®, ev3 Endovascular, 
Plymouth, MN, USA) or the EkoSonic MACH4 Endovascular System (EKOS 
Corporation, Bothell, Washington). In case of residual thrombi, either prolonged CDT 
or PMT alone or with high-pressure intraclot injection of 10 mg rt-PA (PowerPulse® 
technique) using the AngioJet ZelanteDVT® (Boston Scientific, Maple Grove, 
Minnesota) was performed. Before its market introduction in 2015, AngioJet Solent 
Omni® (Boston Scientific) was used. In patients with descending IFDVT limited to the 
5 
 
pelvic or proximal femoral veins, single session  PMT with an AngioJet® device without 
prior CDT was an option (17).  
After thrombus removal, residual vein lesions were identified by digital subtraction 
venography (two orthogonal views) or by intravascular ultrasound if venography was 
equivocal. Significant stenosis was defined by 1) luminal narrowing >50%, 2) absence 
of antegrade flow, or 3) presence of collateral flow at the site of suspected stenosis. 
Residual lesions were treated by balloon angioplasty and stent placement. Depending 
on the affected venous segment and the presence or absence of a compression 
syndrome, the following stents were used: Sinus-XL® stent for the inferior vena cava, 
Sinus-Obliquus® May Thurner stent for compressed common iliac veins, Sinus-XL 
Flex® stent for post-thrombotic iliac or femoral veins (all Optimed, Ettlingen, Germany). 
Stent diameters were 20–24 mm for the inferior vena cava, 14–16 mm for the iliac 




Clinical follow-up visits were routinely performed at our outpatient clinic by vascular 
specialists at 3, 6, 12 months, followed by yearly visits. At each visit, symptoms and 
clinical signs of PTS were recorded using the Villalta score and revised venous clinical 
severity scores (rVCSS).(18, 19) Current AT and recent VTE complications were 
assessed. Patients received a standardized duplex sonography examination at each 
follow-up visit, scanning for thrombotic and post-thrombotic changes of both the treated 
stent segments and the inflow vessels.  
 
Definition of outcomes 
 
Technical success was defined as antegrade flow and maximal luminal stenosis of 
≤30% at termination of the procedure by venography, and evidence of spontaneous 
flow in the treated vein segment by duplex sonography.(20) Primary patency rate was 
defined as the percentage of patients with primary treatment success and without the 
occurrence of either thrombosis of the treated segment or re-intervention to maintain 
patency of the treated segment. Primary assisted patency includes patients after 
venous stent placement who developed restenosis, but not occlusive thrombosis, and 
were successfully retreated. Secondary patency includes also patients after venous 
stent placement who developed re-occlusion of the stent, and were successfully 
retreated.(21)  
In order to distinguish between the bleeding complications due to the endovascular 
intervention and those due to the anticoagulation therapy thereafter, we defined peri-
interventional bleeding complications as bleeding complications within the first 72 h 
and post-interventional bleeding complications as bleeding complications ≥72 h after 
the end of the catheter-based treatment. Bleeding complications were classified 
according to the International Society on Thrombosis and Haemostasis, where major 
bleedings are either 1) fatal bleeding, 2) symptomatic bleeding in a critical area or 
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organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or 
pericardial, or intramuscular with compartment syndrome, and/or 3) bleeding causing 
a drop in hemoglobin level of 20g/L, or leading to transfusion of ≥2 units of packed red 
blood cells. Minor bleedings are less severe bleedings not included in the definition of 
major bleedings.(22) 
Presence of PTS was defined as a total Villalta score of ≥5 points, or the presence of 
a venous ulcer. PTS was classified as mild (Villalta score of 5 to 9 points), moderate 
(10 to 14 points), or severe (≥15 points, or presence of venous ulcers).  
 
Choice of cessation or continuation of anticoagulation therapy 
 
Cessation of AT was considered if all of the following criteria were fulfilled between 3 
and 12 months follow-up: 1) patent venous stents by duplex ultrasound, 2) patent leg 
inflow veins including the femoral, deep femoral and popliteal veins by duplex 
ultrasound, and 3) absence of PTS or presence of mild PTS defined as Villalta score 
< 10 points. The decision on cessation or continuation of AT was revaluated during 
each office visit and followed, in addition to the above criteria, current consensus 
guidelines taking into account all of the following criteria: 1) presence of permanent 
clinical VTE risk factors such as cancer, 2) index event provoked by major surgery or 
trauma, 3) index event occurred in the presence of May-Thurner syndrome (MTS) or 
an alternative iliac vein compression syndrome, 4) history of recurrent VTE, particularly 
if in different locations, 5) known presence of major thrombophilia, i.e. antiphospholipid 
antibody syndrome or homozygous factor V Leiden mutation, 6) risk of bleeding, 7) 
patient compliance, and 8) patient preference. For example, AT was usually extended 
in patients with metastatic cancer or antiphospholipid antibody syndrome or other 
permanent risk factors, and AT was usually discontinued in younger and otherwise 
healthy patients, even if no provoking factor except for a MTS was identified.  
 
Statistical analysis 
Data are presented as means ± standard deviations or absolute numbers and 
percentages for continuous and categorical variables, respectively. Categorical 
outcomes are presented as percentages with 95% confidence intervals (95%CI).  
P-values for differences between the groups were calculated from unpaired t-tests or 
Wilcoxon rank test where appropriate for continuous variables, and chi-square test for 
categorical variables. The cumulative risks of patency rates were estimated with the 
Kaplan-Meier method, and compared by use of a univariate Cox-regression analysis. 
A p-value <0.05 was considered statistically significant. Data were analyzed using 





Baseline characteristics and thrombus extension 
A total of 113 patients with a mean age of 45 ± 20 years were included. In comparison 
to patients with extended-duration AT, patients with limited-duration AT were younger, 
more frequently of female sex, and less frequently had a personal history of VTE or 
cardiovascular comorbidities (Table I). All patients had thrombotic occlusion of the 
common or the external iliac veins, with thrombus extension to the common femoral, 
deep femoral, femoral, popliteal veins, or the inferior vena cava in 81 (72%), 15 (13%), 
55 (49%), 42 (37%), or 23 (20%) patients, respectively, without difference between 
both study groups.  
 
Procedural data 
Primary treatment success was achieved in all patients. Overall, 59 (52%) patients 
were diagnosed with a May-Thurner syndrome, which was more frequent in the limited 
duration AT than in the extended-duration AT group [38 (66%) versus 21 (38%); 
p=0.004). Thrombolysis duration was similar in both groups [17.0 ± 6.1 hours limited-
duration AT versus 18.4 ± 8.2 hours extended-duration AT; p=0.31]. Recombinant 
tissue-type plasminogen activator (rt-PA) doses were significantly lower in patients with 
limited-duration AT [20.6 ± 6.0 mg versus 23.7 ± 8.9 mg; p<0.04]. Thrombolysis 
success, mean number of stents [1.7 ± 1.0 stents in the limited-duration AT group 
versus 1.8 ± 1.3 stents in the extended-duration AT group; p=0.57], and type of 
postinterventional AT [rivaroxaban: 34 (59%) patients in the limited-duration AT group 
versus 36 (65%) patients in the extended-duration AT group;  VKA: 21 (36%) patients 
in the limited-duration AT group versus 14 (25%) patients in the extended-duration AT 
group; others: 3 (5%) patients in the limited-duration AT group versus 5 (9%) patients 
in the extended-duration AT group; p=0.40] was similar in patients with limited and 
extended-duration AT. Overall, 22 (19%) of the 113 patients [13 (22%) in the limited-
duration AT group versus 9 (16%) in the extended-duration AT group; p=0.66] had a 
stent extension into the common femoral vein. None of the patients had stent 
extensions into the deep femoral vein.  
 
Antithrombotic therapy 
All patients received anticoagulation therapy for a minimum duration of 3 months. 
Overall, 70 (62%) patients were treated with rivaroxaban, 35 (31%) with vitamin-K 
antagonists (VKA), and another 8 (7%) with parenteral anticoagulants including low-
molecular-weight heparin, unfractionated heparin, or fondaparinux. All patients with 
parenteral anticoagulants had active malignancies.  
In the limited-duration AT group, AT was terminated at 3, 6, and 12 months in 24 (41%), 





The mean follow-up duration was 26±18 (range 3–77) months, with a longer follow-up 
duration in the limited-duration AT group (31±17 months) than in the extended-duration 
AT group (20±18 months; p=0.02). The mean follow-up duration after cessation of AT 
in the limited-duration AT group was 24±18 (range 3–69). Overall, primary patency 
rates at 12, 24, and 36 months were 86% (95% CI, 77-91%), 80% (95% CI, 70-87%), 
and 73% (95% CI, 61-82%), respectively, with no difference between the limited-
duration AT group [93% (95%CI, 82-97%), 84% (95%CI, 70-92%), and 77% (95%CI, 
60-87%)] and the extended-duration AT group [78% (95%CI, 63-87%), 78% (95%CI, 
63-87%), and 71% (95%CI, 51-84%; p=0.16) (Figure 1A). 
Overall, primary assisted patency rates at 12, 24, and 36 months were 90% (95%CI, 
82-94%), 88% (95%CI, 80-93%), and 84% (95%CI, 73-91%), respectively, with 
significantly higher patency rates in the limited-duration AT group [97% (95%CI, 87-
99%), 94% (95%CI, 84-98%), and 91% (95%CI, 76-97%)] compared to the extended-
duration AT group [81% (95%CI, 66-90%), 81% (95%CI, 66-90%), and 74% (95%CI, 
54-87%); p=0.04] (Figure 1B). 
Overall, secondary patency rates at 12, 24, and 36 months were 96% (95%CI, 90-
99%), 95% (95%CI, 88-98%), and 95% (95%CI, 88-98%), respectively, with no 
significant difference between the limited-duration AT group [100%, 100%, and 100%] 
and the extended-duration AT group [91% (95%CI, 78-97%), 88% (95%CI, 73-95%), 
and 88% (95%CI, 73-95%); p=0.82] (Figure 1C).  
 
Outcomes and complications during follow-up 
 
Clinical follow-up data were available in 107 (95%) patients. Overall, 17 (15%) patients 
developed recurrent VTE during follow-up (equivalent to 7.1 events per 100 patient 
years), with borderline difference between the limited-duration AT group [5 (9%) 
patients; 3.3 events per 100 patient years] and the extended-duration AT group [12 
(22%) patients; 13.1 events per 100 patient years; p=0.05]. Of these recurrent VTE 
events, 13 (76%) occurred during AT [1 (2%) in the limited-duration AT group versus 
12 (22%) in the extended-duration AT group; p<0.001]; equivalent to 10.2 VTE events 
per 100 patient years, whereas in the limited-duration AT group 4 (7%) occurred after 
cessation of AT (equivalent to 3.5 events per 100 patient years). Most of the recurrent 
VTE events were thrombotic stent occlusions, which occurred in 14 (12%) patients, 
with no difference between the limited-duration AT group [4 (7%) patients] and the 
extended-duration AT group [10 (18%) patients; p=0.07]. Patients in the limited-
duration AT group had a significant lower risk of developing recurrent VTE [HR 0.27; 
95%CI 0.10 - 0.78; p=0.015]. The mean time from intervention to stent thrombosis was 
250 ± 268 (range 1 to 890) days. Symptomatic non-fatal PE occurred in 2 (2%) patients, 
one in each group; and 1 (1%) patient in the extended-duration AT group had a 




Major non-intracranial bleeding complications occurred in 3 (3%) patients, all in the 
peri-interventional period, with no difference between the limited-duration AT group [1 
(2%) patient] and the extended-duration AT group [2 (4%) patients; p=0.53]. 
Overall, 92 (86%) patients were free from PTS at latest follow-up, more frequently in 
the limited-duration AT group [53 (95%) patients] than in the extended duration AT 
group [39 (76%) patients; p=0.007; Table 3]. At the latest follow-up, mild PTS was 
present in 14 (13%) patients, with more patients having a mild PTS in the extended-
duration AT group than in the limited-duration AT group [11 (22%) patients versus 3 
(5%) patients; p=0.02]. None developed a severe PTS or leg ulcers. Overall, the mean 
Villalta score at the latest follow-up was 1.6±2.1 points, with higher scores in the 
extended-duration AT group than in the limited-duration AT group (2.3±2.4 points 
versus 1.0±1.6 points; p=0.001), and the mean rVCSS was 2.4±2.4 points, with higher 
scores in the extended-duration AT group than in the limited-duration AT group 




In our study, limited-duration AT seems to be a feasible treatment strategy in selected 
patients with acute IFDVT who underwent early endovascular thrombus removal and 
treatment of underlying venous obstruction by stent placement, with a low rate of 
recurrent VTE and PTS after discontinuation of AT.  
AT remains the fundament of treatment for all patients with acute proximal DVT, and 
primarily aims to reduce the risk of thrombus extension, VTE recurrence, and VTE-
associated mortality. However, conservative therapy alone with AT and elastic 
compression stockings is insufficient to prevent the development of a PTS in a high 
percentage of patients, and patients with acute IFDVT are at greatest risk of recurrent 
VTE and PTS.(2, 23) Recent randomized-controlled trials – the TORPEDO, CaVenT, 
and ATTRACT - suggested that endovascular therapy might be more effective in 
preventing PTS in this population with conflicting results on the rate of VTE recurrence 
(24-26), but did not provide specific information on the role of AT after endovascular 
therapy with or without stents. The 2012 Clinical Practice Guidelines of the Society of 
Vascular Surgery and the American Venous Forum suggest standard conventional AT 
after early thrombus removal therapy, but do not provide recommendations for AT after 
the placement of venous stents(15); the American Heart Association (AHA) considers 
the use of therapeutic anticoagulation with similar dosing, monitoring, and duration as 
for IFDVT patients without stent as reasonable(27); and the 2012 American College of 
Chest Physician (ACCP) suggests the same intensity and duration of AT as in patients 
who do not undergo thrombus removal(28), however, AT following endovascular 
therapy has not been re-addressed in the latest ACCP update in 2016.(14) 
It is generally recommended to stop AT after a minimal duration of 3 months in patients 
with a first-episode proximal DVT related to a major reversible risk factor.(13, 14) 
Cancer patients and patients with unprovoked DVT or previous VTE should be 
considered for extended-duration AT (27, 29), since it has been associated with an at 
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least 80% reduction of recurrence.(30-32) In patients with acute IFDVT, an underlying 
venous obstruction adds an additional risk factor for recurrent DVT, which is not 
integrated in the decision-making process by current guidelines.(13, 14, 27, 28) 
Theoretically, resolving the underlying obstructive vein lesion by a venous stent may 
eliminate the main trigger for recurrence, the PTS, and the need for extended-duration 
AT.(10) However, it is unclear whether a venous stent itself presents a further risk 
factor for re-thrombosis. In our study, 3 of the 58 (5%) patients developed stent 
thrombosis after cessation of AT, challenging the concept of general stent placement 
for descending IFDVT. The role of antiplatelet agents for preventing venous stent 
thrombosis after cessation of AT remains also unclear. Our data show that in selected 
patients with acute IFDVT treated with endovascular early thrombus removal therapy 
and venous stent placement, AT can safely be stopped after 3 to 12 months of therapy 
without an increased VTE rate after stopping. In fact, we report a VTE recurrence rate 
of 3.5 per 100 patient years after cessation of AT for this subgroup. For comparison, a 
meta-analysis of 10.050 patients with symptomatic proximal or distal DVT treated with 
AT only reported a VTE recurrence rate of 7.6 per 100 patient years after cessation of 
AT, while 3.3% of patients developed recurrent VTE events during active treatment for 
6 months.(33) In our study, most thrombotic events occurred during AT, suggesting 
that stent patency may be influenced by other factors including the status of the femoral 
inflow veins.  
There is currently no consensus on the optimal antithrombotic drug regimen after 
venous stent placement.(34) A recent study investigated antithrombotic practices after 
venous stent placement among 106 venous experts in the setting of an acute case of 
IFDVT due to iliac vein compression: short-duration AT (<3 months), limited-duration 
AT (3-12 months), and extended-duration AT was reported in 11%, 73%, and 12%, 
respectively. Four percent of the experts reported antiplatelet therapy only, and 45% 
reported concomitant use of antiplatelet agents temporarily or life-long after 
discontinuation of AT.(16) The TORPEDO, CaVenT and ATTRACT trials did not 
provide specific information on duration of AT in patients who received venous 
stents.(24-26) In our current practice, antiplatelet therapy is not routinely prescribed 
after endovascular therapy for acute DVT. The role of antiplatelet drugs during or after 
stopping AT, or the role of low-dose oral anticoagulants after initial therapeutic dose 
AT in this particular setting needs to be addressed in future randomized trials.  
In our study, most patients remained free from PTS at 2 years in both groups, with a 
lower rate in the extended-duration AT group than in the limited-duration AT group 
(72% versus 98%). The difference in baseline VTE risk between the two study groups, 
such as age and prior VTE (Table I), is the most reasonable explanation for the 
difference in PTS frequency. Our results are favourable compared to the PTS rates 
reported in the three aforementioned major randomized controlled trials, ranging 
between 7% and 43% in the interventional arms.(24-26) A major difference between 
our study and these trials is certainly the rate of venous stent placement, ranging 
between 17% and 30% in these trials while in our study cohort all patients were treated 
with a venous stent.  Furthermore, VKAs were the main anticoagulants used in the 
TORPEDO, CaVenT and ATTRACT trials, whereas rivaroxaban was the most 
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frequently used anticoagulant in our study. Recent data suggest that the latter may be 
more effective in preventing the development of PTS.(35, 36) 
The strengths of our study encompass the implementation of standard operating 
procedures for endovascular intervention and the systematic follow-up. To our 
knowledge, we are the first to provide outcome data for IFDVT patients with stopped 
AT in the presence of venous stents. However, our study has a number of limitations: 
First, sample size was moderate. Second, duration of AT was not randomized but 
determined on an individual basis by treating physicians. Differences in VTE 
recurrence rates between the groups should be interpreted with caution because 
patients in the extended-duration AT group more frequently had VTE risk factors as 
compared to patients with limited-duration AT. Nevertheless, it is important to report 
clinical outcome data for patients with venous stent implants in the presence and 
absence of AT. Third, reporting rates of MTS (52%) in our study might be 
underestimated since diagnosis of iliac vein compression syndromes remain 
challenging in the presence of acute IFDVT. Fourth, this study was performed in one 
Swiss tertiary hospital and the results cannot necessarily be extrapolated to other 
centers or countries. Last, our study is hypothesis generating, and the nature of data 
does not allow any statement regarding superiority of the various treatments.  
In conclusion, in selected patients with acute IFDVT and patent venous stents, 
particularly in younger and otherwise healthy patients with MTS, it appears to be safe 








Figure 1. Kaplan-Meier curves with primary patency rates (A), assisted primary 
patency rates (B), and secondary patency rates (C) for the extended-duration AT and 




Table I. Baseline characteristics 
 
Table I. Baseline characteristics 
 
  
                    
  
Total          
(n = 113) 
Limited- 
duration AT 
group        
(n = 58) 
Extended-
duration AT 
group    
(n = 55) P Value 
Demographics           
 Age (years) 45.7 ± 20.2 38.1 ± 19.5 53.7 ± 17.8 <0.0001 
 Women 70  (62) 43  (74) 27  (49) 0.01 
 Body mass index (kg/m2) 26.0 ± 5.5 24.9 ± 4.5 27.2 ± 6.1 0.1 
Risk factors and comorbidities           
 
Immobilisation* (< 3 
months) 43  (38) 28  (48) 15  (27) 0.02 
 Hormone therapy† 34  (30) 26  (45) 8  (15) 0.001 
 
Recent hospitalisation (< 3 
months) 26  (23) 18  (31) 8  (15) 0.04 
 Current smoking 25  (22) 15  (26) 10  (18) 0.13 
 Arterial hypertension 25  (22) 7  (12) 18  (33) 0.008 
 Obesity 24  (21) 8  (14) 16  (29) 0.05 
 Known previous VTE 24  (21) 5  (9) 19  (35) 0.001 
 
Varicose veins / previous 
surgery for varicose veins 17  (15) 6  (10) 11  (20) 0.15 
 Known thrombophilia 17  (15) 12  (21) 5  (9)  0.10 
 
Recent surgery (< 4 
weeks) 10  (9) 7  (12) 3  (5) 0.23 
 Dyslipidemia 9  (8) 2  (3) 7  (13) 0.07 
 
Severe infection or sepsis 
(< 3 months) 9  (8) 6  (10) 3  (5) 0.34 
 Diabetes 9  (8) 1  (2) 8  (15) 0.01 
 
Active cancer or treatment 
(< 6 months) 8  (7) 2  (3) 6  (11) 0.13 
 Chronic pulmonary disease 7  (6) 4  (7) 3  (5) 0.75 
 Recent trauma (< 4 weeks) 7  (6) 6  (10) 1  (2) 0.06 
Affected leg          0.07 
 Left leg DVT 81  (72) 46  (79) 35  (64) - 
 Right leg DVT 22  (19) 10  (17) 12  (22) - 
 Bilateral DVT 10  (9) 2  (3) 8  (15) - 
Symptoms duration          0.92 
15 
 
 Acute (less than 14 days) 99  (88) 51  (88) 48  (87) - 
 Subacute (14 to 28 days) 14  (12) 7  (12) 7  (13) - 
Thrombus, involved vein 
segments           
 Inferior vena cava 23  (20) 8  (14) 15  (27) 0.08 
 Common iliac vein 85  (75) 46  (79) 39  (71) 0.30 
 External iliac vein 94  (83) 48  (83) 46  (84) 0.90 
 Common femoral vein 81  (72) 40  (69) 41  (75) 0.51 
 Femoral vein 55  (49) 26  (45) 29  (53) 0.40 
 Deep femoral vein 15  (13) 5  (9) 10  (18) 0.13 
 Popliteal vein 42  (37) 19  (33) 23  (42) 0.32 
 Lower leg veins 13  (12) 5  (9) 8  (15) 0.32 
 
Note: data presented as mean ± SD or number (%). *defined as bed ridden for > 72h, plaster 
cast, or long-distance travel of > 6h; †oral contraceptive pill, hormone replacement therapy or 
Tamoxifen use; AT, anticoagulation therapy; CDT, catheter-directed thrombolysis; DVT, deep 





Table II. Clinical outcomes 
Table II. Clinical outcomes 
 
  
Total          
   (n = 113) 
Limited-duration 
AT group   




(n = 55) P Value 
At 6-month follow-up n=93   n=49   n=44    
 Mean Villalta score 1.6 ± 2.0 1.0 ± 1.2 2.2 ± 2.4 0.003 
 No PTS  84  (90) 49  (100) 35  (80) 0.02 
 Mild PTS  8  (9) 0  (0) 8  (18) 0.002 
 Moderate PTS  1  (1) 0  (0) 1  (2) 0.49 
 Severe PTS 0  (0) 0  (0) 0  (0) - 
 Mean rVCSS 2.5 ± 2.2 1.9 ± 1.8 3.2 ± 2.4 0.005 
At 12-month follow-up n=86   n=50   n=36    
 Mean Villalta score 1.5 ± 1.7 1.1 ± 1.3 2.0 ± 1.9 0.01 
 No PTS  81  (94) 50  (100) 31  (86) 0.01 
 Mild PTS  5  (6) 0  (0) 5  (14) 0.01 
 Moderate PTS  0  (0) 0  (0) 0  (0) - 
 Severe PTS 0  (0) 0  (0) 0  (0) - 
 Mean rVCSS 2.1 ± 2.1 1.2 ± 1.3 3.3 ± 2.5 <0.0001 
At 24-month follow-up n=58   n=40   n=18    
 Mean Villalta score 1.6 ± 2.2 1.1 ± 1.5 2.9 ± 3.0 0.003 
 No PTS  52  (90) 39  (98) 13  (72) 0.009 
 Mild PTS  5  (9) 1  (2) 4  (22) 0.03 
 Moderate PTS  1  (1) 0  (0) 1  (6) 0.31 
 Severe PTS 0  (0) 0  (0) 0  (0) - 
 Mean rVCSS 2.2 ± 2.7 1.4 ± 1.9 4.3 ± 3.3 0.0001 
 
Note: data presented as mean ± SD or number (%). AT, anticoagulation therapy; PTS, post-
thrombotic syndrome; rVCSS, revised venous clinical severity score 
